These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 26748215)

  • 1. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
    Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
    Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing.
    Van Gool IC; Ubachs JEH; Stelloo E; de Kroon CD; Goeman JJ; Smit VTHBM; Creutzberg CL; Bosse T
    Histopathology; 2018 Jan; 72(2):248-258. PubMed ID: 28795426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
    Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
    Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
    Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
    Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
    Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
    Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
    Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
    Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
    McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
    Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
    Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.
    Carcangiu ML; Radice P; Casalini P; Bertario L; Merola M; Sala P
    Int J Surg Pathol; 2010 Feb; 18(1):21-6. PubMed ID: 19443869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
    Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
    Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
    Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
    PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
    Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
    BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis.
    Valle L; Hernández-Illán E; Bellido F; Aiza G; Castillejo A; Castillejo MI; Navarro M; Seguí N; Vargas G; Guarinos C; Juarez M; Sanjuán X; Iglesias S; Alenda C; Egoavil C; Segura Á; Juan MJ; Rodriguez-Soler M; Brunet J; González S; Jover R; Lázaro C; Capellá G; Pineda M; Soto JL; Blanco I
    Hum Mol Genet; 2014 Jul; 23(13):3506-12. PubMed ID: 24501277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
    Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
    Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
    BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.